Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the drug than previously predicted.

The Danish company and two executives allegedly expressed confidence CagriSema would cause 25% weight loss on average, but failed to disclose patients could modify their dosing during the trial. Novo would blame this flexibility for diminishing the average weight patients lost in the trial, which later caused its shares to fall, according to the complaint in the US District Court for the District of New Jersey.

Novo ...